pCPA
pan-Canadian Pharmaceutical Alliance
Agency
Evaluation
Outcome
Agency
pCPA
What does pCPA do: Leads public plan negotiations between manufacturers and pCPA for drug prices for all F/P/T drug plans Goal of pCPA: Achieve greater value for publicly funded drug : eprograms and patients through the use of combined negotiating power of participating jurisdictions Mandate: enhance patient access to clinically relevant and cost-effective drug treatmentpCPA Office: supports the work of the pCPA by providing administrative, analytical, negotiations, measurement, policy, and communications support
Evaluation
Phase 1: Initiation
Phase 2: Consideration
Phase 3: Negotiation BIA, cost-effectiveness
Phase 4: Completion
Phase 1: Initiation
For new drugs: pCPA begins once a recommendation is issued by HTA
For existing drugs: pCPA process may be initiated by the pCPA upon review of funded drug products
For line extensions: Manufacturers should contact the pCPAO for inquiries about Line Extensions
Acknowledgement Letter: A letter issued to the Manufacturer, by the pCPA Office, confirming that the pCPA is aware of the recent HTA recommendation(s) related to a Drug and that the Drug has entered the pCPA process.
Phase 2: Consideration
Considers information from HTA, manufacturers, clinicians, patient groups, jurisdictional review as needed by the pCPA
Hold Letter
Engagement Letter
Close Letter
Hold Letter
The Hold Letter indicates that the pCPA has decided not to engage in the negotiation for a specific New Drug for an identified period of time in order to await additional HTA information, other products that are relevant to the negotiation, etc.
Engagement Letter
The Engagement Letter indicates activation of Phase 3: Negotiation, identifies the Lead(s), and identifies the Participating Jurisdiction(s) in the negotiation
Close Letter
The Close Letter indicates that the pCPA will not open a negotiation.
Phase 3: Negotiation BIA, cost-effectiveness
Key evaluation questions :
Is it needed?
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.
Is it affordable?
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.
Phase 4: Completion
Considers information from HTA, manufacturers, clinicians, patient groups, jurisdictional review as needed by the pCPA
LOI
Close Letter
LOI
If mutually agreed upon terms are reached, an LOI will be issued and executed.
PLA
Upon full execution of an LOI, it is the responsibility of the individual Jurisdictions and the Manufacturer to transfer the terms into a PLA.
Close Letter
if mutually agreed upon terms are not reached, the pCPAO has issued a Close Letter to the Manufacturer, indicating that the negotiation is closed.
Outcome
If mutually agreed upon terms are reached, an LOI will be issued and executed.
Upon full execution of an LOI, it is the responsibility of the individual Jurisdictions and the Manufacturer to transfer the terms into a PLA.
if mutually agreed upon terms are not reached, the pCPAO has issued a Close Letter to the Manufacturer, indicating that the negotiation is closed.
Key Evaluation Questions?
Phase 1 Initiation
Phase 2 Consideration
Phase 3 Negotiation
Key Evaluation Questions?
Tab Content
Phase 1 Initiation
pCPA
What does pCPA do: Leads public plan negotiations between manufacturers and pCPA for drug prices for all F/P/T drug plans Goal of pCPA: Achieve greater value for publicly funded drug : eprograms and patients through the use of combined negotiating power of participating jurisdictions Mandate: enhance patient access to clinically relevant and cost-effective drug treatmentpCPA Office: supports the work of the pCPA by providing administrative, analytical, negotiations, measurement, policy, and communications support
Phase 2 Consideration
Phase 1: Initiation
Phase 2: Consideration
Phase 3: Negotiation BIA, cost-effectiveness
Phase 4: Completion
Phase 1: Initiation
For new drugs: pCPA begins once a recommendation is issued by HTA
For existing drugs: pCPA process may be initiated by the pCPA upon review of funded drug products
For line extensions: Manufacturers should contact the pCPAO for inquiries about Line Extensions
Acknowledgement Letter: A letter issued to the Manufacturer, by the pCPA Office, confirming that the pCPA is aware of the recent HTA recommendation(s) related to a Drug and that the Drug has entered the pCPA process.
Phase 2: Consideration
Considers information from HTA, manufacturers, clinicians, patient groups, jurisdictional review as needed by the pCPA
Hold Letter
Engagement Letter
Close Letter
Hold Letter
The Hold Letter indicates that the pCPA has decided not to engage in the negotiation for a specific New Drug for an identified period of time in order to await additional HTA information, other products that are relevant to the negotiation, etc.
Engagement Letter
The Engagement Letter indicates activation of Phase 3: Negotiation, identifies the Lead(s), and identifies the Participating Jurisdiction(s) in the negotiation
Close Letter
The Close Letter indicates that the pCPA will not open a negotiation.
Phase 3: Negotiation BIA, cost-effectiveness
Key evaluation questions :
Is it needed?
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.
Is it affordable?
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.
Phase 4: Completion
Considers information from HTA, manufacturers, clinicians, patient groups, jurisdictional review as needed by the pCPA
LOI
Close Letter
LOI
If mutually agreed upon terms are reached, an LOI will be issued and executed.
PLA
Upon full execution of an LOI, it is the responsibility of the individual Jurisdictions and the Manufacturer to transfer the terms into a PLA.
Close Letter
if mutually agreed upon terms are not reached, the pCPAO has issued a Close Letter to the Manufacturer, indicating that the negotiation is closed.
Phase 3 Negotiation
If mutually agreed upon terms are reached, an LOI will be issued and executed.
Upon full execution of an LOI, it is the responsibility of the individual Jurisdictions and the Manufacturer to transfer the terms into a PLA.
if mutually agreed upon terms are not reached, the pCPAO has issued a Close Letter to the Manufacturer, indicating that the negotiation is closed.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2021 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPA
